Spirito libero amante del divertimento
Turin, Piedmont
Joined July 2014
- Tweets1.5K
- Following705
- Followers221
- Likes3.8K
Antonino Battaglia retweeted
Amazing APCCC prostate consensus statement out today on early prostate cancer. Experts from around the world come together in Lugano to address the most contravercial issues. @Silke_Gillessen @neerajaiims @DrChoueiri @OncoAlert kwnsfk27.r.eu-west-1.awstrac…
Antonino Battaglia retweeted
📊 Prostate cancer treatment is shifting toward risk-adapted care.
From 2010–2023:
🔹 Low risk: radical prostatectomy ↓ ~58%→11%, while expectant management ↑ ~20%→78%.
🔹 Favorable intermediate risk: surgery ↓ as surveillance/expectant management ↑.
🔹 Unfavorable intermediate & high risk: definitive treatment remains key, with radiotherapy playing an increasingly important role.
The takeaway: radical prostatectomy isn’t disappearing—we’re getting better at selecting who truly needs treatment and avoiding overtreatment when it offers little benefit. @JAMA_current
#ProstateCancer #Urology #ActiveSurveillance #RadOnc
Antonino Battaglia retweeted
Great study. Need more of these
My kinda sorta version of this: "try tamsulosin for a few weeks; if it isn't helping, stop it"
Tamsulosin Deprescribing for Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men jamanetwork.com/journals/jam…
Antonino Battaglia retweeted
🚨 PRIMARY2: PSMA-PET moves into the prostate cancer diagnostic pathway
📰Just out in @TheLancetOncol
🧬 660 biopsy-naïve pts w/ suspected significant PCa + PI-RADS 3 MRI or PI-RADS 2 MRI w/ high-risk clinical features
⚖️Randomized to [⁶⁸Ga]Ga-PSMA-11 PET-CT vs systematic transperineal biopsy.
🧭 PRIMARY score 1–2 → surveillance. PRIMARY score 3–5 → PSMA-targeted biopsy.
🎯 PSMA-PET triage was non-inferior for clinically significant PCa detection: 12% vs 16%
✂️ Nearly half avoided biopsy: 49% (163/331).
📉 Clinically insignificant cancer detection dropped substantially: 14% vs 32%.
⚖️ Big implication: fewer biopsies + less overdiagnosis, without losing significant cancers.
💡Caveat: follow-up ongoing; health economics + validation w/ other PSMA tracers needed
🔗shorturl.at/RWxr7
@PCFnews @PCF_Science @renalandurology @UrologyTimes @urotoday
Antonino Battaglia retweeted
Very impressive John K. Lattimer Lecture: Transurethral Robotic en-bloc
TURBT- Challenging the Status
Quo by @jteoh_hk
#bladdercancer surgeons must take note. #aua26
Antonino Battaglia retweeted
@US_FDA approved the first 🩸blood-based MRD 🧬test to guide that decision.
A real milestone. The first of its kind.
Proud to be part of IMvigor011.
Treat who needs it.
Spare who does not.
@NateraGenetics @NEJM @tompowles1 @OncoAlert @MedwatchKate @isliquidbiopsy @ChristianRolfo
Antonino Battaglia retweeted
Urge incontinence trick: toe curl, heel raises, or quick pelvic floor squeezes activate the sacral reflex arc and inhibit the overactive detrusor contraction — buying time to reach the bathroom safely.
Simple. Evidence-based. Life-changing for OAB patients.
drgomezsancha.com
Antonino Battaglia retweeted
Debemos tratar a todos los pacientes con recaída bioquímica?
@APCCC_Lugano
🤖 Made with AI
Antonino Battaglia retweeted
🔹 @IBCG_BladderCA IR stratification → now in @NCCN guidelines
🔹 Our new @BJUIjournal study supports & simplifies it
🔹 3 factors → low / intermediate / high risk IR NMIBC
Easy to use in a busy clinic. No loss in accuracy. A practical tool for real🌎 #BladderCancer @ClevelandClinic @CCLRI @CleClinicUro as always free access >> doi.org/10.1111/bju.70269
Antonino Battaglia retweeted
🚨 ASCO GU 2026: Bladder Cancer’s “Cisplatin-Replacement” Era 🚨
The #ASCOGU26 data confirm it.
Urothelial carcinoma has entered its most transformative phase in 20 years.
Here are the 10 trials redefining practice 👇
1️⃣ KEYNOTE-B15 (EV-304)
Perioperative EV + Pembro vs Gem/Cis
Significant EFS and pCR benefit
Curative setting now ADC + IO driven 🥊
2️⃣ IMvigor011
Atezolizumab improved DFS and OS in ctDNA-positive patients
True MRD-guided adjuvant therapy 🧬
3️⃣ EV-302 (30-mo update)
EV + Pembro
OS 33.8 mo vs 15.9 mo chemo
The new metastatic backbone ⏳
4️⃣ CORE-001
Cretostimogene + Pembro
83% CR in BCG-unresponsive NMIBC
Major bladder-sparing signal 🛡️
5️⃣ NIAGARA biomarker data
Urine tumor DNA detects relapse months before imaging
Dynamic monitoring era 🧪
6️⃣ KEYNOTE-905
EV + Pembro in cisplatin-ineligible MIBC
Platinum eligibility becoming less decisive 📉
7️⃣ Sac-TMT + Pembro
Next-gen Trop-2 ADC entering advanced UC landscape 🧬
8️⃣ SunRISe-2
TAR-200 + Cetrelimab
A serious bladder-preservation contender ✋
9️⃣ KEYMAKER-U04
Triplet exploration
Can we surpass EV + Pembro? 🧪
🔟 RETAIN-1
ctDNA-negative patients safely avoided consolidation surgery
Risk-adapted care validated 🎯
🧠 The Big Shift
Chemo-first → Biomarker-guided
Platinum-defined → ADC + IO backbone
Static staging → Molecular surveillance
Bladder cancer management has fundamentally changed.
#ASCOGU26 #GU26 #OncoTwitter #MedTwitter #BladderCancer #UrothelialCancer
@myESMO @OncoAlert @Larvol @ASCO
🚨 ASCO GU 2026
Top 15 Clinical Trials to Watch
#GU26
🔵 Prostate Cancer
|Precision & Intensification
🧪 CIPHER
Testing platinum as a low-cost option in HRR-mutated mCRPC
☢️ PSMAaddition
¹⁷⁷Lu-PSMA-617 moves into mHSPC
🎯 PEACE-2
Systemic intensification (abiraterone + ADT) with definitive prostate RT
🔗 PEACE-3
Radioligand + ARPI combination in mCRPC
🧬 CAPItello-281
AKT pathway targeting in PTEN-deficient mHSPC
🟢 Bladder & Urothelial Cancer
| ADCs & Bladder Preservation
🧬 KEYNOTE-B15 / EV-304
Perioperative EV + pembrolizumab as a new backbone in MIBC
🧪 VOLGA
IO–ADC triplet strategy in perioperative MIBC
🫙 SunRISe-2
Bladder-sparing TAR-200 + cetrelimab in BCG-unresponsive NMIBC
🧫 Disitamab vedotin + pembrolizumab
ADC expansion beyond enfortumab in HER2-expressing disease
🩸 RETAIN trials (LBA632)
ctDNA-guided, response-adapted bladder preservation in MIBC
🟡 Renal Cell Carcinoma
| Post-IO Sequencing
🧪 LITESPARK-011
Belzutifan combinations after IO–TKI failure
🛡️ LITESPARK-022
HIF-2α inhibition enters the adjuvant setting
🔁 TiNivo-2
IO rechallenge tested rigorously
💊 STELLAR-001
Next-generation TKI (XL092) strategies
🔪 CYTOSHRINK
Response-adapted cytoreductive nephrectomy after systemic therapy
#ASCOGU26 #GUOncology #OncoTwitter #MedTwitter
@OncoAlert @myesmo @esmo_open @asco @Larvol
Antonino Battaglia retweeted
In this infographic you have a structured synthesis of current screening recommendations based on official guidance from:
➡️ United States: U.S. Preventive Services Task Force (USPSTF), American Cancer Society (ACS).
➡️ Europe: European Commission (EU Council Recommendations 2022 update), and position statements from European Society for Medical Oncology (ESMO).
➡️ Only population-based screening with sufficient evidence is included.
Antonino Battaglia retweeted
Congrats to the authors on this RCT. Great to have prospective data showing that in highly selected HGT1 (pT0 reTURBT & -ve cytology), active surveillance was non-inferior to induction BCG for invasive relapse
Yes, ⬆️ recurrences w AS but v useful data for counselling pts
📢 New publication in European Urology
We are pleased to highlight a new study published in European Urology, titled "Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial".
👏 Congratulations to Hiroshi Kitamura et al. on this excellent contribution, together with all co-authors.
🔗 Read the full article here:
👉 lnkd.in/ePEvrQDY
#EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology
Antonino Battaglia retweeted
Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial - European Urology Oncology euoncology.europeanurology.c…
Antonino Battaglia retweeted
Localised prostate cancer just changed. Again.
ESMO 2026 brings clarity on who to observe, who to escalate, and which trials actually matter 👇
🧠 Diagnosis
MRI before biopsy is standard
High-resolution US is a valid alternative (RCT n=678)
🧭 Low risk
Active surveillance is safe
ProtecT 15-yr data shows similar survival vs RP/RT
☢️ Radiotherapy
Shorter is better
CHHiP ➜ moderate hypofractionation
HYPO-RT-PC ➜ ultra-hypofractionation
PACE-B ➜ SBRT works in selected IR disease
📈 High risk
RT + long-term ADT saves lives
SPCG-7 | NCIC/MRC
Dose escalation improves OS (GETUG-AFU 18)
🚨 Very high-risk / cN1
RT + ADT + abiraterone is the new benchmark
STAMPEDE delivers MFS + OS benefit
🔁 Biochemical recurrence
Avoid routine adjuvant RT
Early salvage RT preferred
RADICALS-RT | RAVES | GETUG-AFU 17
High-risk BCR? Intensify
EMBARK supports enzalutamide + ADT
🧠 Bottom line
Risk-adapted care > overtreatment
Imaging-driven decisions
Escalate only when trials prove benefit
📖 Full paper in comment ⬇️
#OncoTwitter #MedTwitter #ProstateCancer #GUOncology
@OncoAlert @myesmo @esmo_open @asco @OncBrothers
Antonino Battaglia retweeted
|GnRH antagonists give faster LUTS relief in prostate cancer
#PROSCA25 #GlobalForum25
Urinary symptoms matter in men starting RT plus ADT. Across multiple trials (Anderson, Mason, Axcrona), one signal is crystal clear:
🟦 Degarelix and other antagonists drop IPSS faster than LHRH agonists + bicalutamide
🟦 Benefit is strongest in men with high baseline IPSS
🟦 Improvement appears independent of prostate shrinkage
🟦 Likely linked to direct action on BPH cells and the bladder
🟦 Helpful during RT when LUTS often flare
Clinical takeaway:
When a patient needs quick urinary relief, an antagonist can give a noticeably faster improvement than agonist based ADT.
#OncoTwitter #MedTwitter #ProstateCancer @OncoAlert @asco @esmo_open @myesmo @mirrorsmed
Antonino Battaglia retweeted
Lessons learned after an incredible 20,000 prostatectomy cases: amazing update @vipulpatelmd #ipcs25
Antonino Battaglia retweeted
YouTube link to attend the Milan Roundtable on liquid biomarkers in GU Cancers @SanRaffaeleMI @IBCG_BladderCA @GTumors
youtube.com/live/f5YG4d-vTHY…
Antonino Battaglia retweeted
New State-of-the-Art Review: “The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies” - just published in the November issue of European Urology @EUplatinum by Dr. Benjamin Maughan and colleagues. It’s a great honor to be part of this amazing team, led by Dr.Shilpa Gupta.
Liquid biopsies offer many promising areas of potential clinical utility. We believe there is now sufficient validation to justify their use in patients with genitourinary cancers. We recommend somatic tumor testing for all patients with metastatic genitourinary malignancies, given both disease-specific and disease-agnostic indications. Such testing may also provide important prognostic insights that can guide patient counseling, though certain applications still require validation in prospective, biomarker-driven clinical trials.
We strongly encourage the extensive use of liquid biopsy testing when indicated, aiming to improve outcomes and support further research.
The clinical utility of liquid biopsies is expected to expand further as additional indications are evaluated and validated.
Future applications may include patient selection for adjuvant therapy in renal cell carcinoma and/or urothelial carcinoma, screening of high-risk populations, and new predictive assays for systemic therapy. Each new application will need to be validated in appropriately designed clinical studies as part of the ongoing effort to advance personalized medicine and improve patient outcomes.
The full article is available here: sciencedirect.com/science/ar…
@maughanonc @LDyrskjot @PGrivasMDPhD @EAntonarakis @bilenma @tbivala1 @dr_coops @shilpaonc
Antonino Battaglia retweeted
🧬 Urine tumor DNA to stratify recurrence risk after atezolizumab in BCG-unresponsive NMIBC
In a secondary analysis of the SWOG S1605 trial, urine tumor DNA (utDNA) profiling with the UroAmp assay was used to stratify the risk of response to treatment with atezolizumab in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer.
🔹 In patients with high-risk NMIBC that recurred after prior BCG treatment, UroAmp can identify which patients are at a high risk of cancer recurrence before and during the treatment with atezolizumab.
🔹 Patients with positive ut-DNA were less likely to respond to treatment and had a higher chance of cancer recurrence.
🔹 UroAmp supports therapy personalization through patient-specific molecular data
These findings highlight utDNA as a promising biomarker for treatment monitoring and risk stratification, potentially helping to guide therapeutic strategies in BCG-unresponsive NMIBC.
European Urology, Vol. 88 (2025), pp. 430–434
DOI: buff.ly/V8YgEWi
💬An accompanying editorial appears in the same issue
European Urology, Vol. 88 (2025), pp. 435–436; Check it out: buff.ly/T0kjMXY
#EuropeanUrology #BladderCancer #UroOncology #Biomarkers #Immunotherapy #Atezolizumab #BCGunresponsive #UroAmp
